These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). Micheletti R; Mattera GG; Rocchetti M; Schiavone A; Loi MF; Zaza A; Gagnol RJ; De Munari S; Melloni P; Carminati P; Bianchi G; Ferrari P J Pharmacol Exp Ther; 2002 Nov; 303(2):592-600. PubMed ID: 12388640 [TBL] [Abstract][Full Text] [Related]
46. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 2nd communication: in vivo cardiovascular effects and bioavailability in dogs. Yoshimura A; Koide Y; Yoshioka K; Hino M; Sugawara H; Sakato M; Endoh M Arzneimittelforschung; 1999 May; 49(5):407-11. PubMed ID: 10367102 [TBL] [Abstract][Full Text] [Related]
47. Hemodynamic and myocardial energetic effects of CK-3197, a selective positive inotropic agent. Greenberg S; Touhey B J Cardiovasc Pharmacol; 1991 Jan; 17(1):145-53. PubMed ID: 1708048 [TBL] [Abstract][Full Text] [Related]
48. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. Asanoi H; Ishizaka S; Kameyama T; Ishise H; Sasayama S J Cardiovasc Pharmacol; 1994 Feb; 23(2):268-74. PubMed ID: 7511757 [TBL] [Abstract][Full Text] [Related]
49. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 3rd communication: stereoselectivity of the enantiomers in cardiovascular effects. Sugawara H; Hino M; Yoshimura A; Yoshioka K; Sakato M; Endoh M Arzneimittelforschung; 1999 May; 49(5):412-9. PubMed ID: 10367103 [TBL] [Abstract][Full Text] [Related]
50. ORM-3819 promotes cardiac contractility through Ca(2+) sensitization in combination with selective PDE III inhibition, a novel approach to inotropy. Nagy L; Pollesello P; Haikala H; Végh Á; Sorsa T; Levijoki J; Szilágyi S; Édes I; Tóth A; Papp Z; Papp JG Eur J Pharmacol; 2016 Mar; 775():120-9. PubMed ID: 26872993 [TBL] [Abstract][Full Text] [Related]
51. Cardiac and hemodynamic effects of intravenous R 80122, a new phosphodiesterase III inhibitor, in anesthetized and awake dogs. Van de Water A; d'Aubioul J; Van Gerven W; de Chaffoy de Courcelles D; Freyne E; Xhonneux R; Reneman RS; Janssen PA Arch Int Pharmacodyn Ther; 1992; 316():60-74. PubMed ID: 1530374 [TBL] [Abstract][Full Text] [Related]
52. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Ekelund UE; Harrison RW; Shokek O; Thakkar RN; Tunin RS; Senzaki H; Kass DA; Marbán E; Hare JM Circ Res; 1999 Sep; 85(5):437-45. PubMed ID: 10473673 [TBL] [Abstract][Full Text] [Related]
53. Differential effects of dobutamine and a phosphodiesterase inhibitor on early diastolic filling in patients with congestive heart failure. Nagata K; Iwase M; Sobue T; Yokota M J Am Coll Cardiol; 1995 Feb; 25(2):295-304. PubMed ID: 7829780 [TBL] [Abstract][Full Text] [Related]
54. In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, in various animals. Yamashita S; Hosokawa T; Kojima M; Mori T; Yabuuchi Y Arzneimittelforschung; 1984; 34(3A):342-6. PubMed ID: 6331464 [TBL] [Abstract][Full Text] [Related]
56. Studies on the mechanism of positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with vasodilating properties. Holck M; Thorens S; Muggli R; Eigenmann R J Cardiovasc Pharmacol; 1984; 6(3):520-30. PubMed ID: 6202981 [TBL] [Abstract][Full Text] [Related]
57. Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart. Satoh K; Satoh Y; Imagawa J; Taira N Jpn Heart J; 1993 Mar; 34(2):213-9. PubMed ID: 8315818 [TBL] [Abstract][Full Text] [Related]
58. Combined inotropic and bradycardic effects of a sodium channel enhancer in conscious dogs with heart failure: a mechanism for improved myocardial efficiency compared with dobutamine. Shen W; Gill RM; Jones BD; Zhang JP; Corbly AK; Steinberg MI J Pharmacol Exp Ther; 2002 Nov; 303(2):673-80. PubMed ID: 12388650 [TBL] [Abstract][Full Text] [Related]
59. Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. Bethke T; Klimkiewicz A; Kohl C; von der Leyen H; Mehl H; Mende U; Meyer W; Neumann J; Schmitz W; Scholz H J Cardiovasc Pharmacol; 1991 Sep; 18(3):386-97. PubMed ID: 1720839 [TBL] [Abstract][Full Text] [Related]
60. Mechanical and electrophysiological effects of a hydroxyphenyl-substituted tetrahydroisoquinoline, SL-1, on isolated rat cardiac tissues. Chang GJ; SU MJ; Lee PH; Lee SS; Liu KC Can J Physiol Pharmacol; 1995 Nov; 73(11):1651-60. PubMed ID: 8789420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]